Insilico Medicine receives NMPA IND clearance for innovative oral candidate ISM8969/HT-001, the brain-penetrant NLRP3 inhibitor co-developed with Hygtia Therapeutics - EurekAlert!
Insilico Medicine receives IND approval from FDA for ISM8969, an AI-empowered potential best-in-class NLRP3 inhibitor - EurekAlert!
